Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (KNSA)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Mar 30, 2026Investment Snapshot
- Trading 430% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- ROE of 5.7% — below-average profitability
- Revenue growing at 60% annually
Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (KNSA) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $3.4 billion . Key value metrics: P/E ratio 105.7, P/B ratio 5.98, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares — Fundamental Analysis Summary
Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (KNSA) is currently trading 430% above its Graham Number of $8.63, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 105.7x.
On financial health, KNSA shows a moderate Piotroski F-Score of 6/9, and modest return on equity of 5.7% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.35.
StockPik's composite Value Score for KNSA is 54/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
KNSA reports a high gross margin of 86.9% (sector average: 33.5%) and a modest operating margin of 8.1%.
KNSA shows revenue growing at 60% year-over-year, with earnings growing at 237%.